Skip to content

Alveolar Macrophage Programming Following Endotoxin Exposure

Alveolar Macrophage Programming Following Endotoxin Exposure

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03859050
Enrollment
25
Registered
2019-03-01
Start date
2019-03-18
Completion date
2032-07-31
Last updated
2025-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS, Human

Brief summary

The histologic hallmarks of lung inflammation include accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capillary integrity and accumulation of edema fluid in the interstitium and airspaces. Accordingly, for alveolar repair to occur inflammation must be halted, debris and inflammatory cells removed, injured tissue cells replaced, and capillary barrier function re-established. Macrophages are key players in all of these. Here the investigators hypothesize that resident alveolar macrophages and recruited macrophages serve completely different functions, acting independently (i.e. division of labor) yet cooperatively (synergism).

Interventions

OTHERbronchoscopy with intrabronchial administration of lipopolysaccharide

The PI will administer intrabronchial LPS into the lungs of healthy volunteers and then obtaining macrophages by bronchoalveolar lavage (BAL) 24, 48, 72, 96, or 120 hours later.

Sponsors

National Jewish Health
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

1. Written, informed consent 2. Age 18-50

Exclusion criteria

1. Current or recent illness (past 2 weeks) 2. Presence or prior history of cardiac, pulmonary or systemic disease 3. Bleeding disorder, use of systemic anticoagulants or antiplatelet therapy 4. American Society of Anesthesiology (ASA) class 2 or greater 5. Immunocompromised state (HIV, immunoglobulin deficiency, systemic immunosuppressants) 6. Use of any inhaled substance, including tobacco, marijuana, e-cigarrettes, cocaine, methamphetamines, or toxic vapors in the past 3 months or greater than 10 pack-year smoking history 7. Alcohol use disorder or greater than 7 drinks/week for women or greater than 14 drinks/week for men in the past 3 months 8. Allergy or prior adverse reaction to lidocaine, midazolam or fentanyl 9. Abnormal spirometry or electrocardiogram at time of screening 10. Pregnant (based on urine pregnancy test) or breast feeding

Design outcomes

Primary

MeasureTime frameDescription
Resident alveolar macrophages and recruited macrophages will be distinguished from one another using multi-parameter flow cytometry, and the relative proportions enumerated7 daysResident and recruited macrophages will be purified using fluorescence activated cell sorting (FACS) and subjected to RNA sequencing.

Countries

United States

Contacts

Primary ContactKara Mould
mouldk@njhealth.org303-398-1787

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026